Riociguat as bridging therapy to pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: a retrospective cohort study.

Zhaohua ZhangJingwen LiuYanan ZhenXiaopeng LiuMingyuan XuJunyu MaJianyan WenPeng Liu

Published in: Journal of thoracic disease (2024)

The use of riociguat as bridging therapy demonstrated hemodynamic improvement before PEA in patients with high preoperative PVR. However, no additional benefits in postoperative mortality or hemodynamics were observed.

Keyphrases

pulmonary hypertension
pulmonary artery
pulmonary arterial hypertension
patients undergoing
risk factors
stem cells
type diabetes
cardiovascular disease
coronary artery disease
bone marrow
replacement therapy